BiotechTube

Atu027

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Solid Tumors

Conditions

Advanced Solid Tumors

Trial Timeline

Jun 1, 2009 → Sep 1, 2012

NCT ID
NCT00938574

About Atu027

Atu027 is a phase 1 stage product being developed by Silence Therapeutics for Advanced Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00938574. Target conditions include Advanced Solid Tumors.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00938574Phase 1Completed

Competing Products

20 competing products in Advanced Solid Tumors

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25

Other Products from Silence Therapeutics

SLN360 + PlaceboPhase 2
44
SLN124 + PlaceboPhase 1/2
33
Atu027 & gemcitabine in lead in safety period + Atu027 & gemcitabine in treatment arm 1 + Atu027 & gemcitabine in treatment arm 2Phase 1/2
33
SLN124 + PlaceboPhase 1
25
SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as PlaceboPhase 1
25